Longitudinal Proteomic Signatures of Dupilumab and Tralokinumab Treated Atopic Dermatitis Patients
Wojciech Francuzik, Kristijan Pažur, Margitta Worm · 2026
Read Longitudinal Proteomic Signatures of Dupilumab and Tralokinumab Treated Atopic Dermatitis Patients by Wojciech Francuzik, Kristijan Pažur, Margitta Worm (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13612374.txt.
Description
Wojciech Francuzik, Kristijan Pažur, and Margitta Worm track blood proteins in eczema patients on two biologic drugs, in a paper dated twenty twenty-six. Ten patients took dupilumab and ten took tralokinumab for twelve months. Blood samples came at the start and after a year of care.
A 440-protein panel mapped each patient's pattern against healthy controls. Both drugs shrank the core allergy-type swelling signal, cutting marker CCL17. Dupilumab shifted a broader set, lifting proteins of the other immune arm. The drugs pushed some repair and metabolism proteins in opposite ways.
Catalog record
| CREATOR | Wojciech Francuzik, Kristijan Pažur, Margitta Worm |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |